Companies Cryptocurrencies
Insmed Inc
Insmed Inc
Exchange: Nasdaq Global Select
IPO Date: 15/02/1991
CEO: Mr. William Lewis
Biotechnology Healthcare 🔗
  • INSM
  • 20.89
  • 2496710144
    market cap
  • 1.1700001
If you bought

shares of Insmed Inc (INSM) on
You would have made
Old Price $12 Current Price $12

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 373 full-time employees. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The firm’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Address: 700 US Highway 202/206 Bridgewater NEW JERSEY 08807-1704

Stay updated.